Fmr LLC Sells 49,698 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Fmr LLC lessened its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 0.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,078,746 shares of the company’s stock after selling 49,698 shares during the quarter. Fmr LLC owned about 10.62% of Structure Therapeutics worth $164,856,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Spire Wealth Management purchased a new position in Structure Therapeutics in the 4th quarter valued at approximately $243,000. JPMorgan Chase & Co. grew its position in shares of Structure Therapeutics by 302.3% in the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock valued at $1,489,000 after purchasing an additional 25,500 shares in the last quarter. Barclays PLC raised its stake in shares of Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after purchasing an additional 31,815 shares during the period. Franklin Resources Inc. lifted its holdings in Structure Therapeutics by 9.4% during the 3rd quarter. Franklin Resources Inc. now owns 706,106 shares of the company’s stock worth $30,991,000 after purchasing an additional 60,397 shares in the last quarter. Finally, Exome Asset Management LLC bought a new position in Structure Therapeutics in the 3rd quarter worth about $5,274,000. Institutional investors own 91.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GPCR shares. JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. William Blair assumed coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $15.90 on Friday. The firm has a market capitalization of $911.75 million, a PE ratio of -21.49 and a beta of -1.35. Structure Therapeutics Inc. has a 52-week low of $13.22 and a 52-week high of $62.74. The firm has a fifty day moving average of $20.98 and a 200 day moving average of $29.19.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. On average, sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.